I HAVE PARKINSON'S DISEASES AND THOUGHT IT WOULD BE NICE TO HAVE A PLACE WHERE THE CONTENTS OF UPDATED NEWS IS FOUND IN ONE PLACE. THAT IS WHY I BEGAN THIS BLOG.

I COPY NEWS ARTICLES PERTAINING TO RESEARCH, NEWS AND INFORMATION FOR PARKINSON'S DISEASE, DEMENTIA, THE BRAIN, DEPRESSION AND PARKINSON'S WITH DYSTONIA. I ALSO POST ABOUT FUNDRAISING FOR PARKINSON'S DISEASE AND EVENTS. I TRY TO BE UP-TO-DATE AS POSSIBLE.

I AM NOT RESPONSIBLE FOR IT'S CONTENTS. I AM JUST A COPIER OF INFORMATION SEARCHED ON THE COMPUTER. PLEASE UNDERSTAND THE COPIES ARE JUST THAT, COPIES AND AT TIMES, I AM UNABLE TO ENLARGE THE WORDING OR KEEP IT UNIFORMED AS I WISH. IT IS IMPORTANT TO UNDERSTAND I AM A PERSON WITH PARKINSON'S DISEASE. I HAVE NO MEDICAL EDUCATION,

I JUST WANT TO SHARE WITH YOU WHAT I READ ON THE INTERNET. IT IS UP TO YOU TO DECIDE WHETHER TO READ IT AND TALK IT OVER WITH YOUR DOCTOR. I AM JUST THE COPIER OF DOCUMENTS FROM THE COMPUTER. I DO NOT HAVE PROOF OF FACT OR FICTION OF THE ARTICLE. I ALSO TRY TO PLACE A LINK AT THE BOTTOM OF EACH ARTICLE TO SHOW WHERE I RECEIVED THE INFORMATION SO THAT YOU MAY WANT TO VISIT THEIR SITE.

THIS IS FOR YOU TO READ AND TO ALWAYS KEEP AN OPEN MIND.

PLEASE DISCUSS THIS WITH YOUR DOCTOR, SHOULD YOU HAVE ANY QUESTIONS, OR CONCERNS. NEVER DO ANYTHING WITHOUT TALKING TO YOUR DOCTOR FIRST..

I DO NOT MAKE ANY MONEY FROM THIS WEBSITE. I VOLUNTEER MY TIME TO HELP ALL OF US TO BE INFORMED.

I WILL NOT ACCEPT ANY ADVERTISEMENT OR HEALING POWERS, HEALING FROM HERBS AND ETC. UNLESS IT HAS GONE THROUGH TRIALS AND APPROVED BY FDA. IT WILL GO INTO SPAM.

THIS IS A FREE SITE FOR ALL WITH NO ADVERTISEMENTS

THANK YOU FOR VISITING! TOGETHER WE CAN MAKE A DIFFERENCE!

Wednesday, July 23, 2014

A Few Ways We May Stop Parkinson's

FoxFeed Blog

A Few Ways We May Stop Parkinson's

Posted by Maggie McGuire, July 22, 2014

Alpha-synuclein: that sticky protein that clumps in the brain cells of people with Parkinson’s. Scientists think that aggregates of alpha-synuclein — called Lewy bodies — are toxic, killing off cells and leading to PD symptoms. Therefore, avoiding or breaking up Lewy bodies is a major focus of research.

The Michael J. Fox Foundation funds a robust portfolio of projects that target alpha-synuclein, and we’re leading efforts to understand more about this protein, why it clumps together in the first place and how new cells are “infected” with Lewy bodies.

The projects we support that target alpha-synuclein to stop or prevent Parkinson’s disease take one of four approaches:

Lower alpha-synuclein levels overall: Scientists hypothesize that less alpha-synuclein means less opportunity for Lewy bodies, so they are exploring ways to prevent the body from making this protein, such as interfering with gene signaling. Complicating this approach is that we don’t yet know the normal function of alpha-synuclein, and thereby the effect of wiping it out. However, pre-clinical models without alpha-synuclein appear to function normally, which is promising.
- Read more about a project that took this approach.

Break up Lewy bodies in the cells: Since clumps of alpha-synuclein clog up cells, researchers are working on a therapy that would break up Lewy bodies (like untying a knot) and allow the cells to function properly.
- Learn about a project that’s using this method.

Help the cells clear out Lewy bodies: A cell may stay healthy if it is able to rid itself of the Lewy bodies before they have harmful effects. Scientists are working on therapies to either directly degrade Lewy bodies or to bolster the cells’ cleaning mechanisms to flush out the alpha-synuclein clumps.
- Read more about one target in this category.

Catch Lewy bodies on the move: One theory proposes that Lewy bodies are released from cells and infiltrate others to spread the disease. Another suggests that the diseased cells give off a signal to other cells that makes the alpha-synuclein in those secondary cells start to clump. Either way, if a drug could stop the disease from spreading between cells, it would stop its progression.
- Learn about a clinical trial of an antibody against Lewy bodies.

“We take a varied approach because we don’t want to put all our eggs in one basket,” said Kuldip Dave, PhD, who directs the MJFF alpha-synuclein portfolio. “We’re after a drug that can stop or slow the progression of Parkinson’s, and alpha-synuclein is a primary target. More approaches to treat the disease give us more chances of success.”